公开(公告)号：EP1768982A2

公开(公告)日：2007-04-04

申请号：EP05768263.5

申请日：2005-06-29

申请人： Amgen Inc.

发明人： FARTHING, Christopher N. ,  FAULDER, Paul ,  FRENKEL, Alexander David ,  HARRISON, Martin James ,  JIAO, Xianyun ,  KAYSER, Frank ,  KOPECKY, David J. ,  LIU, Jinqian ,  LIVELY, Sarah E. ,  SHARMA, Rajiv ,  SHUTTLEWORTH, Stephen Joseph

IPC分类号： C07D487/00 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D487/04

摘要： Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.

公开(公告)号：EP1768986A2

公开(公告)日：2007-04-04

申请号：EP05763716.7

申请日：2005-06-29

申请人： Amgen Inc.

发明人： BUCHANAN, John L. ,  BUCKNER, William H. ,  BURKITT, Simon A. ,  DIMAURO, Erin F. ,  FARTHING, Christopher N. ,  FRENKEL, Alexander David ,  HARRISON, Martin J. ,  KAYSER, Frank ,  LIU, Jinqian ,  LIVELY, Sarah E. ,  MARSHALL, Teresa L. ,  MCGOWAN, David C. ,  SHARMA, Rajiv ,  SHUTTLEWORTH, Stephen Joseph ,  ZHU, Xiaotian

IPC分类号： C07D498/04 ,  A61K31/519

CPC分类号： C07D491/04 ,  C07D495/04

摘要： The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).

公开(公告)号：EP1786782B1

公开(公告)日：2010-03-31

申请号：EP05790029.2

申请日：2005-08-11

申请人： Amgen Inc.

发明人： BERGERON, Philippe ,  FARTHING, Christopher N. ,  JONES, Stuart D. ,  LIEBESCHUETZ, John W. ,  LIVELY, Sarah E. ,  MCGEE, Lawrence R. ,  MCKENDRY, Sharon ,  SHEPPARD, David ,  YOUNG, Stephen C.

IPC分类号： C07D239/48

CPC分类号： C07D239/47 ,  C07D213/75 ,  C07D237/22 ,  C07D239/42 ,  C07D239/46 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/58

摘要： Compounds, compositions and methods are provided that are useful in. the treatment or preventionTof a condition or disorder mediated by PPARϜ or PPARδ. In particular, the compounds of the invention modulate the function of PPARϜ or PPARδ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis. The subject, compounds include bisaryl-sulfonamides that have general formula (I): wherein Ar, R1, X, Y, Z. W, L, B and R2 are described herein.

公开(公告)号：EP1786782A2

公开(公告)日：2007-05-23

申请号：EP05790029.2

申请日：2005-08-11

申请人： Amgen Inc.

发明人： BERGERON, Philippe ,  FARTHING, Christopher N. ,  JONES, Stuart D. ,  LIEBESCHUETZ, John W. ,  LIVELY, Sarah E. ,  MCGEE, Lawrence R. ,  MCKENDRY, Sharon ,  SHEPPARD, David ,  YOUNG, Stephen C.

IPC分类号： C07D239/48

CPC分类号： C07D239/47 ,  C07D213/75 ,  C07D237/22 ,  C07D239/42 ,  C07D239/46 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/58

摘要： Compounds, compositions and methods are provided that are useful in. the treatment or preventionTof a condition or disorder mediated by PPARϜ or PPARδ. In particular, the compounds of the invention modulate the function of PPARϜ or PPARδ. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis. The subject, compounds include bisaryl-sulfonamides that have general formula (I): wherein Ar, R1, X, Y, Z. W, L, B and R2 are described herein.